Shattuck Labs will present at two investor conferences in December 2024, focusing on its novel cancer and autoimmune disease therapeutics.
Quiver AI Summary
Shattuck Labs, Inc., a biotechnology company focused on developing therapeutics targeting tumor necrosis factor superfamily receptors for cancer and chronic immune-related diseases, announced participation in two investor conferences in December 2024. CEO Dr. Taylor Schreiber will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, and engage in a fireside chat at the Evercore 7th Annual HealthCONx Conference on December 4. Live webcasts of both events will be available on the company's website, along with archived replays for 90 days. Shattuck Labs is known for its innovation in treatments for autoimmune and inflammatory diseases, particularly its lead program, SL-325, a first-in-class DR3 antagonist antibody.
Potential Positives
- Participation in two prestigious investor conferences enhances visibility and credibility within the biotechnology sector.
- Presentation by the CEO demonstrates leadership engagement and promotes the company's innovative therapeutic pipeline.
- The announcement of developing a potentially first-in-class antibody could attract interest from investors seeking groundbreaking treatments in autoimmune and cancer therapies.
- Live webcasts provide transparency and accessibility for investors, fostering a proactive communication strategy.
Potential Negatives
- Participation in investor conferences may indicate a need for the company to bolster investor confidence amid potential concerns regarding its pipeline or financial performance.
- No specific updates were provided on the progress of its treatments, which could raise doubts about the company's development timeline or milestones.
- The reliance on webcasts for information dissemination may limit direct engagement with investors, potentially leading to misinterpretations or a lack of clarity regarding the company's strategic direction.
FAQ
What conferences will Shattuck Labs participate in December 2024?
Shattuck Labs will participate in the Piper Sandler Healthcare Conference and the Evercore HealthCONx Conference.
Who is presenting for Shattuck Labs at the conferences?
Dr. Taylor Schreiber, M.D., Ph.D., the Chief Executive Officer, will present at both conferences.
When are the presentations scheduled?
The Piper Sandler presentation is on December 3, 2024, and the Evercore conference on December 4, 2024.
Will the presentations be available for live streaming?
Yes, a live webcast will be available on the Investors section of Shattuck's website.
How long will the webcasts be archived?
The webcasts will be archived for up to 90 days following their respective presentation dates.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STTK Insider Trading Activity
$STTK insiders have traded $STTK stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STTK stock by insiders over the last 6 months:
- TAYLOR SCHREIBER (Chief Executive Officer) has traded it 2 times. They made 2 purchases, buying 50,900 shares and 0 sales.
- TYLER BROUS has traded it 2 times. They made 2 purchases, buying 8,416 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STTK Hedge Fund Activity
We have seen 44 institutional investors add shares of $STTK stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROSIGHT MANAGEMENT, LP added 1,008,726 shares (+21.6%) to their portfolio in Q3 2024
- LAURION CAPITAL MANAGEMENT LP removed 661,038 shares (-100.0%) from their portfolio in Q2 2024
- TWO SIGMA ADVISERS, LP added 217,700 shares (+601.4%) to their portfolio in Q3 2024
- NORTHERN TRUST CORP added 216,203 shares (+201.0%) to their portfolio in Q3 2024
- UBS GROUP AG added 212,905 shares (+1795.0%) to their portfolio in Q3 2024
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 155,000 shares (+5.6%) to their portfolio in Q3 2024
- PINNACLE ASSOCIATES LTD removed 141,977 shares (-23.7%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced that company management will participate in two investor conferences in December 2024.
Presentation Details
Conference: Piper Sandler 36th Annual Healthcare Conference
Format: Corporate Presentation
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: December 3, 2024
Time: 12:30 p.m. ET
Conference: Evercore 7th Annual HealthCONx Conference
Format: Fireside chat with covering analyst, Jonathan Miller, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: December 4, 2024
Time: 8:45 a.m. ET
A live webcast of the presentation and fireside chat will be available on the Investors section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases and cancer. The Company is developing a potentially first-in-class antibody for the treatment of IBD and other inflammatory autoimmune diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com .
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)